Compositions and methods for identifying, modulating and monitoring drug targets in muscular disease
AssigneeSomaLogic, Inc.
InventorsLarry Gold, Kirk DeLisle, David Sterling, Edward Brody, Britta Singer, Robert Mehler
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to customized therapy for disease. The present disclosure also relates to aptamer-based compositions and methods for identifying, modulating and monitoring drug targets in muscular disease (e.g., Duchenne muscular dystrophy).
Claims45
A method for treating a subject for muscular dystrophy comprising administering, to a subject in need, a therapeutic effective amount of a therapeutic agent selected from GDF-11, RELT, CD55, WFIKKN1, gelsolin, fibroblast activation protein alpha (FAP), protein jagged-1 (JAG1), bone sialoprotein 2 (IBSP), ADAM metallopeptidase domain 9 (ADAM9), cadherin-5 (CDH5), neural cell adhesion molecule L1-like protein (CHL1), osteomodulin (OMD), contactin-5 (CNTN5), and combinations thereof.
A method for treating a subject for muscular dystrophy comprising administering, to a subject in need, a therapeutic effective amount of a protein analog or agonist of GDF-11, RELT, CD55, WFIKKN1, gelsolin, fibroblast activation protein alpha (FAP), protein jagged-1 (JAG1), bone sialoprotein 2 (IBSP), ADAM metallopeptidase domain 9 (ADAM9), cadherin-5 (CDH5), neural cell adhesion molecule L1-like protein (CHL1), osteomodulin (OMD), and/or contactin-5 (CNTN5).
A method for determining a treatment course of action, comprising:
- a) assaying a tissue sample from a subject diagnosed with muscular disease to identify altered levels of one or more proteins relative to the level of said proteins in normal tissue;
- and
- b) administering one or more treatments that targets one or more of said proteins with altered expression.
A method for determining a treatment course of action, comprising:
- a) assaying a tissue sample from a subject diagnosed with muscular disease to identify altered levels of one or more proteins selected from GDF-11, RELT, CD55, WFIKKN1, gelsolin, fibroblast activation protein alpha (FAP), protein jagged-1 (JAG1), bone sialoprotein 2 (IBSP), ADAM metallopeptidase domain 9 (ADAM9), cadherin-5 (CDH5), neural cell adhesion molecule L1-like protein (CHL1), osteomodulin (OMD), and contactin-5 (CNTN5) relative to the level of said proteins in normal tissue;
- and
- b) administering one or more treatments that targets one or more of said proteins with altered expression.
A method for treating a disease, comprising:
- a) assaying a biological sample from a subject diagnosed with a disease to identify altered levels of one or more proteins relative to the level of said protein in a reference sample;
- and
- b) administering one or more treatments that target one or more of said proteins with altered expression to said subject.
A method for monitoring treatment of a disease, comprising:
- a) assaying a biological sample from a subject diagnosed with a disease to identify altered levels of one or more proteins relative to the level of said protein in a reference sample;
- b) administering one or more treatments that target one or more of said proteins with altered expression to said subject;
- and
- c) repeating step a) one or more times.
A method for monitoring progression of a muscular disease, comprising assaying a biological sample from a subject diagnosed with a disease to identify altered levels of one or more proteins listed in Table 2 relative to the level of said protein in a reference sample.
A method for monitoring progression of a muscular disease, comprising assaying a first biological sample from a subject with a muscular disease and assaying a second biological sample from the subject, wherein the first and second biological samples were taken at a first time point and a second time point, to identify altered levels of one or more proteins listed in Table 2 at the second time point relative to the first time point.
Dependencies are inferred from the claim text.